Condition
GEN1 Gene Mutation
Total Trials
3
Recruiting
0
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 2 (1)
Trial Status
Active Not Recruiting1
Completed1
Suspended1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT04859543Not ApplicableCompleted
Pediatric Prospective Personalized Immune and Target Identification Trial
NCT04030559Phase 2Active Not Recruiting
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
NCT04975048Not ApplicableSuspended
SREBF1 Polymorphism and Egg Yolk on Cardiovascular Disease Risk in Healthy Young Adults: a Randomised, Two-period, Single Blinded, Crossover Trial
Showing all 3 trials